DRAXIMAGE DTPA
LOE Approachingkit for the preparation of technetium tc 99m pentetate
NDAINJECTIONINJECTABLE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DRAXIMAGE DTPA (kit for the preparation of technetium tc 99m pentetate) by Jubilant Therapeutics is lead chelating activity [moa]. Approved for pulmonary embolism. First approved in 1989.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DRAXIMAGE DTPA is a kit for preparing Technetium Tc-99m pentetate, a diagnostic radiopharmaceutical used in nuclear medicine imaging. It functions as a lead chelator that binds to technetium for diagnostic visualization. The product is indicated for pulmonary embolism detection via injection.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), commercial teams are likely consolidating focus; expect selective hiring in high-margin markets only.
Mechanism of Action
Lead Chelating Activity
Pharmacologic Class:
Lead Chelator
Indications (1)
Career Relevance
With zero linked job postings and approaching LOE, career opportunities on DRAXIMAGE DTPA are severely limited and declining. This product offers minimal growth trajectory and is best suited for professionals seeking stable, maintenance-phase roles rather than high-visibility launches.
Diagnostic Product Manager
Worked on DRAXIMAGE DTPA at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.